Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 14, 2024, at 8:55 a.m. PT, corporate presentation H.C. Wainwright 2nd Annual BioConnect Investor Conference (New York, New York) Monday, May 20, 2024, at 11:00 a.m. ET, fireside chat A webcast o...
Costco Wholesale Corporation Reports April Sales Results ISSAQUAH, Wash., May 08, 2024 (GLOBE NEWSWIRE) -- Costco Wholesale Corporation (“Costco” or the “Company”) (Nasdaq: COST) today reported net sales of $19.80 billion for the retail month of April, the four weeks ended May 5, 2024, an increase of 7.1 percent from $18.48 billion last year. Net sales for the first 35 weeks were $166.44 billion, an increase of 7.0 percent from $155.62 billion last year. Comparable sales were as follows: 4 Weeks 35 Weeks U.S.5.8% 4.1% Canada5.2% 7.7% Other International5.1% 9.1% Total Company5.6%...
Alector Reports First Quarter 2024 Financial Results and Provides Business Update Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease, on track for Q4 2024 Strengthened leadership team with key appointments: Neil Berkley, M.S., M.B.A., named Chief Business Officer; Errol De Souza, Ph.D., and Mark Altmeyer, M.B.A., join Board of Directors $562.1 million in cash, cash equivalents and investments provide runway through 2026 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALE...
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. Individuals ma...
Two Directors at LendingTree Inc sold 10,750 shares at between 49.080USD and 49.300USD. The significance rating of the trade was 87/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...
Major Risk-On Developments; Bullish Outlook Intact Over the past two weeks we have discussed the possibility that further downside was limited (4/23/24 Compass) and the mounting evidence that suggests the lows may be in for this pullback (4/30/24 Compass). Major risk-on developments for the broad equity market have continued to roll in over the past week, which we discuss below. As a result, we continue to believe the lows are in for this pullback, and we see the pullback to the 100-day MA on t...
Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update -- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- -- Phase 3 trial evaluating setmelanotide in hypothalamic obesity remains on track for topline data readout in 1H 2025; dosing of first patients in Japan anticipated in 2Q 2024 -- -- Secured $150 million in convertible preferred stock fina...
While we believe Genco remains a discounted entry into dry bulk exposure at a P/NAV of 0.77x, the recent share price rise and freight market strength have put more focus on the downside risks to our dry bulk sector outlook. Genco is set for a solid first half of the year on our estimates, but we find the risk/reward less attractive medium-term. Hence, we have downgraded to HOLD (BUY), but raised our target price to USD22.6 (22.5).
PITTSBURGH--(BUSINESS WIRE)-- Alcoa Corporation President and Chief Executive Officer William F. Oplinger will participate in a webcast session at the Bank of America Global Metals, Mining & Steel Conference in Miami, Florida, on Tuesday, May 14, 2024. At 3:00 p.m. EDT, Oplinger will deliver a presentation regarding Alcoa’s business, the announced acquisition of Alumina Limited, and outlook in the current market, including factors that could affect the Company’s present quarter’s financial results. His presentation will be followed by a brief question-and-answer session. A slide presentati...
Real-World, Long-Term Data Demonstrate Sustained Benefits of Aquablation Therapy for Men with Benign Prostatic Hyperplasia Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizes SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data show...
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting -- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.